East meets West: The winning combination against BRAF V600E metastatic colorectal cancer

doi:10.5306/wjco.v16.i5.102223

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=11

May 24, 2025 (publication date) through May 19, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. May 24, 2025; 16(5): 102223
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.102223

East meets West: The winning combination against BRAF V600E metastatic colorectal cancer

Wen-Ming Liu, Xiao-Bing Li

Wen-Ming Liu, Department of Gastrointestinal Surgery, The First People’s Hospital of Tianmen, Tianmen 431700, Hubei Province, China

Xiao-Bing Li, Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, Hubei Province, China

Author contributions: Liu WM drafted the manuscript; Li XB made contributions to the collection, analysis and summary of the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.

Supported by the Natural Science Foundation of Hubei Province, No. 2019CFC929.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Xiao-Bing Li, MD, PhD, Assistant Professor, Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 South Zhuodaoquan Road, Hongshan District, Wuhan 430079, Hubei Province, China. lixiaobing0629@126.com

Received: October 12, 2024
Revised: February 10, 2025
Accepted: February 19, 2025
Published online: May 24, 2025
Processing time: 219 Days and 15.2 Hours

Core Tip

Core Tip: Bian et al’s study demonstrates that integrated treatment with tolerated toxicity significantly improves survival in patients with BRAF mutant advanced colorectal cancer compared to traditional Western medicine alone, especially for certain subgroups. However, while this study provides new evidence supporting combined therapies, it also has limitations, such as unclear mechanisms of action, lack of detailed treatment protocols, and a small sample size. Summarizing these new findings and addressing the study’s issues will not only aid in the clinical application of integrated treatments for colorectal cancer but also promote the development of personalized therapies for this disease.